Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

PURPOSE: Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Conlon, Kevin C., Lugli, Enrico, Welles, Hugh C., Rosenberg, Steven A., Fojo, Antonio Tito, Morris, John C., Fleisher, Thomas A., Dubois, Sigrid P., Perera, Liyanage P., Stewart, Donn M., Goldman, Carolyn K., Bryant, Bonita R., Decker, Jean M., Chen, Jing, Worthy, Tat'Yana A., Figg, William D., Peer, Cody J., Sneller, Michael C., Lane, H. Clifford, Yovandich, Jason L., Creekmore, Stephen P., Roederer, Mario, Waldmann, Thomas A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268254/
https://ncbi.nlm.nih.gov/pubmed/25403209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3329
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados